老年急诊患者肠外酮咯酸镇痛的安全性
本研究为回顾性研究,纳入≥65岁接受肠外酮咯酸镇痛的成人及3:1匹配对照,最终分析480例(酮咯酸组120例,对照组360例)。主要终点为30天内胃肠道出血、颅内出血、急性失代偿性心衰、急性冠脉综合征、透析、输血或死亡,酮咯酸组2例(1.7%) vs 对照组14例(3.9%),p=0.38,OR 2.39(95%CI 0.54-10.66)。两组均无透析或死亡。次要终点血肌酐升高≥1.5倍基线在7天和30天分别仅见于酮咯酸组1/13(7.7%)和1/23(4.4%),对照组均为0.0%,差异无统计学意义。结论认为在特定老年人群中单次肠外酮咯酸未增加不良结局。
要点
- ≥65岁急诊患者单次肠外酮咯酸镇痛,30天主要不良事件发生率1.7%(2/120) vs 对照3.9%(14/360),p=0.38,OR 2.39(95%CI 0.54-10.66)。
- 两组均未发生透析或死亡。
- 7天内血肌酐升高≥1.5倍基线:酮咯酸组7.7%(1/13) vs 对照组0.0%,p=0.29。
- 30天内血肌酐升高≥1.5倍基线:酮咯酸组4.4%(1/23) vs 对照组0.0%,p=0.22。
- 研究为回顾性设计,仅纳入特定老年人群,结论需谨慎解读。
适用人群与场景
- 年龄≥65岁的急诊科成人患者,接受肠外酮咯酸镇痛治疗及匹配对照。
研究设计与关键结果
- 研究类型:回顾性研究,最终分析480例,酮咯酸组120例,对照组360例(3:1匹配)。
- 主要终点(30天内胃肠道出血、颅内出血、急性失代偿性心衰、急性冠脉综合征、透析、输血或死亡):酮咯酸组2/120(1.7%) vs 对照组14/360(3.9%),p=0.38,OR 2.39(95%CI 0.54-10.66)。
- 两组均无透析或死亡发生。
- 次要终点(7天内血肌酐升高≥1.5倍基线):酮咯酸组1/13(7.7%) vs 对照组0.0%,p=0.29。
- 次要终点(30天内血肌酐升高≥1.5倍基线):酮咯酸组1/23(4.4%) vs 对照组0.0%,p=0.22。
证据类型、等级与局限
- 证据类型:回顾性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在特定老年人群中单次肠外酮咯酸镇痛未增加心血管、胃肠道或肾脏不良结局发生率。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To assess the safety of a single dose of parenteral ketorolac for analgesia management in geriatric emergency department (ED) patients.
METHODS: This was a retrospective study of all administrations of parenteral ketorolac to adults ≥65 years of age and matched controls. The primary outcome was the occurrence of any of the following adverse events within 30 days of the ED visit: gastrointestinal bleeding, intracranial bleeding, acute decompensated heart failure, acute coronary syndrome, dialysis, transfusion, and death. The secondary outcome was the occurrence of an increase in serum creatinine of ≥1.5 times baseline within 7 and 30 days of the ED visit.
RESULTS: There were 480 patients included in the final analysis, of which 120 received ketorolac (3: 1 matching). The primary outcome occurred in 14 of 360 patients who did not receive ketorolac and 2 of 120 ketorolac patients (3.9% vs 1.7%, p = 0.38; OR 2.39, 95% CI 0.54-10.66). There was no occurrence of dialysis or death in either group. The secondary outcome occurred in 1 of 13 and 1 of 23 ketorolac patients with both a baseline serum creatinine and a measure within 7 and 30 days, respectively, but did not occur in patients who did not receive ketorolac (7 days: 7.7% vs 0.0%, p = 0.29; 30 days: 4.4% vs 0.0%, p = 0.22).
CONCLUSION: The use of single doses of parenteral ketorolac for analgesia management was not associated with an increased incidence of adverse cardiovascular, gastrointestinal, or renal adverse outcomes in a select group of older adults.
参考来源
- Anderson GL, Mattson AE, Brown CS, et al. Safety of parenteral ketorolac use for analgesia in geriatric emergency department patients. Am J Emerg Med. 2019. PMID: 31201117. doi:10.1016/j.ajem.2019.06.009
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。